ArticleBMC public health2026
Public health implications of allergic rhinitis information on YouTube and Bilibili: a cross-cultural analysis of content quality, engagement, and seasonal trends.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAllergic Rhinitis (AR) affects over 500 million people globally, posing a significant public health burden. Video-sharing platforms like YouTube and Bilibili have become primary sources of health information. This study aimed to compare content quality, user engagement, and alignment with seasonal search trends of AR-related videos on these two culturally distinct platforms.
methodsWe retrieved the top 200 AR-related videos from each platform (keywords: "allergic rhinitis" for YouTube, "" for Bilibili) published between January 2022 and January 2025. After applying predefined exclusion criteria (irrelevance, non-English YouTube videos, out-of-timeframe, advertisements), 240 videos (91 YouTube, 149 Bilibili) were retained. Quality was assessed using the Patient Education Material Assessment Tool (PEMAT), Video Information Quality Index (VIQI), Global Quality Scale (GQS), and the Modified DISCERN Scale (mDISCERN). We also integrated Google Trends and Baidu Index data to analyze video characteristics, engagement, and correlations with seasonal search trends.
resultsAR-related video quality was generally low, though YouTube scored significantly higher than Bilibili in median PEMAT-Total (76.5 vs. 71.4), GQS (4 vs. 3), and mDISCERN (3 vs. 1) (all P < 0.001). YouTube featured more content from medical professionals (33.3%, n = 30/91), whereas Bilibili's was predominantly from non-professionals (61.4%, n = 92/149). Bilibili showed higher user engagement, with greater interactions through comments and donations. Both platforms showed spring and autumn search peaks, coinciding with allergen seasons. A moderate positive correlation emerged between Bilibili videos and Baidu Index (r = 0.37; P = 0.03), while YouTube videos correlated strongly with Google Trends (r = 0.63; P = 0.03). Professional content scored higher on both platforms, but treatment-related Bilibili videos correlated negatively with search volume (r = - 0.69; P = 0.01), signaling potential misinformation risks during peak periods.
conclusionsFor AR-related videos, YouTube offers better content quality, while Bilibili excels in user engagement. Both platforms need improved content quality and coverage. A seasonal "demand-content" loop exists between AR search trends and video content, carrying misinformation risks during peak periods. We recommend year-round promotion of evidence-based content, adding medical warnings to misleading information, and encouraging collaboration between medical professionals and social media creators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.